Cynthia is a seasoned investment professional with nineteen years’ experience in venture capital. Prior to co-founding AllosteRx, Cynthia was a General Partner with TVM Capital, a global fund with main offices in Munich and Montreal. She was recruited to TVM from VG Partners where she was partner and co-head of the life sciences fund. Cynthia has taken active roles on boards of companies including Acer Therapeutics (NASDAQ: ACER), Cytochroma (acquired by OPKO Health), VisualSonics (acquired by SonoSite, now FujiFilm SonoSite), and Trillium Therapeutics (NASDAQ: TRIL, acquired by Pfizer). Cynthia is currently board director of CCRM Enterprises portfolio companies Morphocell Technologies, developing cell therapies for liver disease, and Apiary Therapeutics, a start-up developing cell-based protein factory technologies. Along with her role as Chair of the Fibrocor Board, Cynthia is also Board Director at Profound Medical (NASDAQ:PROF, TSX:PRN). Dr. Lavoie received a PhD from McGill University and MBA from the Rotman School of Management at the University of Toronto.

Keno has over 25 years of Biotech experience spanning operations (CEO of Brandaris Therapeutics), investing (private and public equities at M Ventures and Omega Funds), investment banking (Piper Sandler), management consulting (IQVIA), and medical research (MRC). Prior to joining BGV, Keno was as Managing Director and Vice President at M Ventures responsible for Biotech investments (Biopharma and Life Sciences).
Keno is a Fellow of the Royal Society of Medicine, holds a PhD in Genetics from University College in London and an MBA from INSEAD. He is the inventor of a patent in the field of neurosciences. His research in lipid metabolism has been published in the top scientific journal Nature.

He has been actively involved in forming and managing start-ups, preparing and executing on business plans, raising early-stage capital and in- and out-licensing activities. Before joining Toronto Innovation Acceleration Partners, Parimal was a healthcare analyst with a boutique investment bank, where he conducted equity research on publicly traded biotechnology companies in Canada and the U.S. He has also led commercialization activities out of BC Women’s and Children’s Hospital as part of his role at the University of British Columbia’s Industry Liaison Office and was a research scientist at a start-up biotechnology company involved in drug discovery targeting ABC Transporters. Parimal received his MBA from Simon Fraser University and his M.Sc. from the University of British Columbia. He currently sits on the boards of TRIUMF Innovations, Zucara Therapeutics, Cohesys Inc. and Vasomune Therapeutics and is an observer on the board of Encycle Therapeutics.

During his >40 year career in biotech, he held positions at Genentech Inc. (postdoctoral scientist), Syngenta and DSM (Research and Project Management), Crucell (Director of Business Development), and Invitrogen Corporation (Managing Director of Corp Dev Europe).
From 2005 until his retirement in January 2023, Andre was CBO and member of the Galapagos Executive Committee, responsible for M&A, BD and IP. Andre negotiated 15 large pharma drug discovery partnerships, and was the lead negotiator of the landmark partnership with Gilead in 2019. As part of the Galapagos growth strategy, Andre negotiated 7 acquisitions and led the divestment of 4 parts of the CRO business.
He currently serves as a member of the supervisory boards of Artax Inc (Boston, MA), Mimetas BV and Sapreme BV (both located in Holland).